Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio reported Q1 2026 financial results, highlighting a cash balance of $225.6 million that provides a runway into 2028 following a $144 million public offering in February. The company's lead program, tibulizumab, remains on track with Phase 2 trials in HS (TibuSHIELD) and systemic sclerosis (TibuSURE) targeting topline data readouts in Q4 2026 and H1 2027, respectively.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Drug Name
- tibulizumab (ZB-106)
- Guidance
- Cash runway expected to fund planned operations through at least the end of 2028
- Revenue Yoy
- 0
- Deal Value Usd
- 144000000
- Phase Of Trial
- Phase 2
- Net loss
- 24200000
- Ga expenses
- 10800000
- Rd expenses
- 14700000
- Cash position
- 225600000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.